Alembic Pharmaceuticals reported 19% drop in net profit to Rs 133 crore despite a 14% rise in net sales to Rs 1,475 crore in Q2 FY23 over Q2 FY22.
On the segmental front, API revenue was Rs 294 crore (up 23% YoY). In the Formulations business, US revenue was Rs 418 crore (up 20% YoY), India revenue was Rs 549 crore (up 8% YoY) and Ex-US revenue was Rs 215 crore (up 9% YoY).
EBIDTA fell by 12% to Rs 231 crore in Q2 FY23 from Rs 263 crore in Q2 FY22. EBIDTA margin was 16% in Q2 FY23 as against 20% in Q2 FY22.
R&D expenses aggregated to Rs 168 crore in the second quarter. Capex spend in the July-September 2022 quarter was Rs 131 crore.
Pranav Amin, managing director, Alembic Pharmaceuticals, said: It was a satisfactory quarter led by growth in all the verticals of the company, in particular the API business outperformed with a 23% growth during the quarter.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world.
The scrip rose 2.53% to currently trade at Rs 631.65 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app